信号通路介导乳腺癌内分泌治疗耐药的研究进展(4)
[16] Yardley D A，Noguchi S，Pritchard K I，et al.Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer：BOLERO-2 final progression-free survival analysis[J].Adv Ther，2013，30(10)：870-884.
[17] Crowder R J，Phommaly C，Tao Y，et al.PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer[J].Cancer Res，2009，69(9)：3955-3962.
[18] Maira S M，Pecchi S，Huang A，et al.Identification and characteriza tion of NVP-BKM120， an orally available pan-class Ⅰ PI3-kinase inhibitor[J].Mol Cancer Ther，2012，11(2)：317-328.
, http://www.100md.com
[19] Baselga J，Campone M，Osborne K，et al.PI3K inhibitor improves PFS in BELLE-2 trial[J].Cancer Discov，2016，6(2)：115-116.
[20] Bendell J C，Rodon J，Burris H A，et al.Phase Ⅰ，Dose-Escalation Study of BKM120， an Oral Pan-Class Ⅰ PI3K Inhibitor，in Patients With Advanced Solid Tumors[J].Journal of Clinical Oncology，2012，30(3)：282-290.
[21] Hong D S，Bowles D W，FalchookK G S，et al.A multicenter phase I trial of PX-866，an oral irreversible phosphatidylinositol 3-kinase inhibitor，in patients with advanced solid tumors[J].Clin Cancer Res，2012， 18(15)：4173-4182.
, 百拇医药
[22] Bowles D W，Ma W W，Senzer N，et al.A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours[J].British Journal of Cancer，2013，109(5)：1085-1092.
[23] Kaufman B，Mackey J R，Clemens M R，et al.Trastuzumab plus anas trozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive，hormone receptor-positive metastatic breast cancer：results from the randomized phase Ⅲ TAnDEM study[J].
, http://www.100md.com
J Clin Oncol，2009，27(33)：5529-5537.
[24] Johnston S，Pippen J Jr，Pivot X，et al.Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer[J].J Clin Oncol，2009，27(33)：5538-5546.
[25] Warenius H M，Kilburn J D，Essex J W，et al.Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4[J].Molecular Cancer，2011，10(1)：72.
, 百拇医药
[26] Steger G G，Gnant M，Bartsch R.Palbociclib for the treatment of postmenopausal breast cancer-an update[J].Expert Opin Pharmacother，2016， 17(2)：255-263.
[27] Finn R S，Crown J P，Lang I，et al.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combinatiaon with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive，HER-2 negative，advanced breast cancer(PALOMA-1/TRIO-18)：a randomized phase 2 study[J].Lancet Oncol，2015，16：25-35., http://www.100md.com(范凤凤 郭宇)
[17] Crowder R J，Phommaly C，Tao Y，et al.PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer[J].Cancer Res，2009，69(9)：3955-3962.
[18] Maira S M，Pecchi S，Huang A，et al.Identification and characteriza tion of NVP-BKM120， an orally available pan-class Ⅰ PI3-kinase inhibitor[J].Mol Cancer Ther，2012，11(2)：317-328.
, http://www.100md.com
[19] Baselga J，Campone M，Osborne K，et al.PI3K inhibitor improves PFS in BELLE-2 trial[J].Cancer Discov，2016，6(2)：115-116.
[20] Bendell J C，Rodon J，Burris H A，et al.Phase Ⅰ，Dose-Escalation Study of BKM120， an Oral Pan-Class Ⅰ PI3K Inhibitor，in Patients With Advanced Solid Tumors[J].Journal of Clinical Oncology，2012，30(3)：282-290.
[21] Hong D S，Bowles D W，FalchookK G S，et al.A multicenter phase I trial of PX-866，an oral irreversible phosphatidylinositol 3-kinase inhibitor，in patients with advanced solid tumors[J].Clin Cancer Res，2012， 18(15)：4173-4182.
, 百拇医药
[22] Bowles D W，Ma W W，Senzer N，et al.A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours[J].British Journal of Cancer，2013，109(5)：1085-1092.
[23] Kaufman B，Mackey J R，Clemens M R，et al.Trastuzumab plus anas trozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive，hormone receptor-positive metastatic breast cancer：results from the randomized phase Ⅲ TAnDEM study[J].
, http://www.100md.com
J Clin Oncol，2009，27(33)：5529-5537.
[24] Johnston S，Pippen J Jr，Pivot X，et al.Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer[J].J Clin Oncol，2009，27(33)：5538-5546.
[25] Warenius H M，Kilburn J D，Essex J W，et al.Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4[J].Molecular Cancer，2011，10(1)：72.
, 百拇医药
[26] Steger G G，Gnant M，Bartsch R.Palbociclib for the treatment of postmenopausal breast cancer-an update[J].Expert Opin Pharmacother，2016， 17(2)：255-263.
[27] Finn R S，Crown J P，Lang I，et al.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combinatiaon with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive，HER-2 negative，advanced breast cancer(PALOMA-1/TRIO-18)：a randomized phase 2 study[J].Lancet Oncol，2015，16：25-35., http://www.100md.com(范凤凤 郭宇)
参见：首页 > 医疗版 > 疾病专题 > 普通外科 > 乳腺癌